Magenta Therapeutics Appoints Amy Ronneberg, President of Be The Match BioTherapies, to Board of Directors
Published: Apr 06, 2018
“I am delighted to welcome Amy to the Magenta Board of Directors. Amy brings more than 20 years of operational and financial leadership, and we believe that her significant experience with the leading global bone marrow transplant organization will be important as the company continues to explore ways to change the lives of transplant patients,” said Michael Bonney, Chair of the Board of Directors, Magenta Therapeutics. “Alison Lawton has been a valuable member of the Magenta Board, and we are pleased that she has agreed to serve in an advisory capacity for the Company.”
Amy Ronneberg is the president of Be The Match BioTherapies®, an organization partnering with companies pursuing new life-saving treatments in cellular therapy. She also serves as the chief financial officer of the National Marrow Donor Program® (NMDP)/Be The Match®, a non-profit organization dedicated to helping patients access life-saving bone marrow transplants, and parent company of Be The Match BioTherapies. Since joining the NMDP/Be The Match in 2013, Amy has formulated a new organizational operating model and established international operations. Prior to joining NMDP/Be The Match, Amy served as executive vice president, chief financial officer and chief operating officer of North American Membership Group, a media company. She also held a variety of financial and operational leadership roles at Capella University. Earlier in her career, Amy worked for Ernst & Young as an audit manager. Amy holds a B.B.A. in accounting from University of Wisconsin-Eau Claire, and an M.B.A. from Capella University.
Amy will join Magenta’s existing Board of Directors: Jason Gardner, Jeff Albers, Michael Bonney, Bruce Booth, Alexis Borisy, Blake Byers, Tom Daniel and David Scadden.
About Bone Marrow Transplant
Healthy bone marrow stem cells and the blood cells they create are crucial for survival, but certain diseases can affect the bone marrow, interfering with its ability to function properly. A bone marrow transplant is a process to replace unhealthy bone marrow with healthy bone marrow stem cells. Bone marrow transplant can save the lives of patients with blood cancers and genetic diseases and is a potential cure for patients with severe refractory autoimmune diseases. Currently bone marrow transplant is still associated with risk, toxic side effects, and complexity for patients that could benefit from the procedure. Magenta is working to address these challenges through its integrated portfolio of therapeutics.
About Magenta Therapeutics
Magenta Therapeutics is a biotechnology company developing therapeutics to revolutionize bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of unmet need, Magenta Therapeutics is pioneering an integrated approach to extend the curative power of bone marrow transplant to more patients, by making the process more effective, safer, and easier. Founded by internationally recognized leaders in bone marrow transplant medicine, Magenta Therapeutics was launched in 2016 by Third Rock Ventures and Atlas Venture and is headquartered in Cambridge, Mass. For more information, please visit www.magentatx.com.